Pharmacotherapies targeting RAAS, including ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists (MRAs) or renin inhibitors, may decrease high BP among patients with obesity [12, 13]. Here, ACE is linked to obesity due to melanocortin 4 receptor deficiency.